Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Endocrinology

Articles with lock require a GLG News subscription
Joseph Bass Posted January 9, 2008
Alogliptin on the diabetes horizon.
Analysis of: Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S. | www.pipelinereview.com
Author: Joseph Bass, Division Head of Endocrinology and Metabolism Evanston Northwestern Healthcare
Diabetes is on the rise globallyExisting oral therapeutics have significant drawbacks but are cheap (generic) and some have been in use for many years.
Posted January 3, 2008
Osteoporosis Treatment: What's next?
Analysis of: Galapagos announces osteoporosis collaboration with Lilly | www.pipelinereview.com
Author: GLG Member Program Contributor
Lilly needs new treatments and strategies  to maintain position as industry leader.
Posted January 3, 2008
Serotonin and satiety is very interesting
Analysis of: Biovitrum has Successfully Completed the First Phase I Trial of its 5-HT6 Receptor Antagonist (BVT.74316) | www.pipelinereview.com
Author: GLG Member Program Contributor
An interesting observation made as a consequence of the widespread use of serotonin specific reuptake inhibitors (SSRI) in clinical psychiatry is that these medications tend to affect appetite.  SSRIs can cause either weight gain or loss.  There was a time when they were extensively used in...
Posted January 2, 2008
Galpagos & Lilly collaboration: osteoporosis
Analysis of: Galapagos announces osteoporosis collaboration with Lilly | www.pipelinereview.com
Author: GLG Member Program Contributor
1.   Did this collaboration increase the stock value of Galapagos or Lilly ?  If so, why ? If not, why not ? 2.   Like all Big Pharma Cos, Lilly is very vulnerable to the demands of Wall Street for quaterly dividends and has a shallow pipeline of new drugs in development. 3.  ...
Posted December 28, 2007
Nothing new, but important
Analysis of: Older and cheaper pills just fine for diabetes | www.reuters.com
Author: GLG Member Program Contributor
Although, it really is nothing new, it is important info.  Metformin should be the first step.
Posted December 26, 2007
A welcome reality check
Analysis of: Older and cheaper pills just fine for diabetes | www.reuters.com
Author: GLG Member Program Contributor
This article confirms what I have long suspected.  We doctors spend entirely too much valuable time trying to separate clinical truth from marketing messages.  And many (but not all) of us are tired of hearing our patients complain that they are not using their medicines because they cannot...
Posted December 26, 2007
Joint collaboration between Galapagos NV and Eli Lilly and Company (NYSE:LLY)- Is this going to work ?
Analysis of: Galapagos announces osteoporosis collaboration with Lilly | www.pipelinereview.com
Author: GLG Member Program Contributor
The collaboration between Galapagos NV (Euronext & LSE: GLPG) and Eli Lilly and Company (NYSE:LLY) is expected to show significant progress to develop bone formation for the treatment of osteoporosis at a global level. The news published in the www.pipeline.review shows the complimentary functions...
Posted December 17, 2007
Another nail in its coffin
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
Avandia needs definitive studies of its safety to ressurect itself. This study leads to a further reason for no longer using it. People may disagree, but those of us on the front lines are hard pressed using a drug with so much liability baggage.
Posted December 17, 2007
More Glucose Sensor Progress
Analysis of: Dexcom says gets FDA OK to calibrate glucose monitoring system | www.reuters.com
Author: GLG Member Program Contributor
Dexcom is really the leader of the pack of the glucose sensors, in a variety of ways.  For such a small company to be in the lead, is quite impressive.
Posted December 10, 2007
thiazolidinedione demise will support Januvia use
Analysis of: Diabetes drug link to weak bones | news.bbc.co.uk
Author: GLG Member Program Contributor
This makes it easier for me to avoid mention or suggestion to my patients to try glitazones. I am having an easier time now with prior approvals of Januvia after only a trial of Metformin and sulfonylureas
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next101 to 110 of 367

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-10-07T13:45:18.680